Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study.

INTRODUCTION: Persons living with HIV (PLWH) are at higher risk for cardiovascular disease (CVD) events than uninfected persons. Current risk-stratification methods to define PLWH at highest risk for CVD events are lacking. METHODS: Using tandem flow injection mass spectrometry, we quantified plasma levels of 60 metabolites in 24 matched pairs of PLWH [1:1 with and without known coronary artery disease (CAD)]. Metabolite levels were reduced to interpretable factors using principal components analysis. RESULTS: Factors derived from short-chain dicarboxylacylcarnitines (SCDA) (p = 0.08) and glutamine/valine (p = 0.003) were elevated in CAD cases compared to controls. CONCLUSION: SCDAs and glutamine/valine may be valuable markers of cardiovascular risk among persons living with HIV in the future, pending validation in larger cohorts.

Duke Scholars

Author Nwora Lance Okeke Medicine, Infectious Diseases

Author Olga Ilkayeva Medicine, Endocrinology, Metabolism, and Nutrition

Author Susanna Naggie Medicine, Infectious Diseases

Author Svati Hasmukh Shah Medicine, Cardiology